Related Experiment Videos
[Clinical studies on biapenem (L-627) in the pediatric field]
1Department of Pediatrics, Aomori Prefectural Central Hospital.
Abstract:
Biapenem (L-627) was given intravenously to 17 children with acute bacterial infections including 3 with purulent tonsillitis, 1 with bronchitis, 4 with pneumonia, 2 with sepsis, 3 with pyelonephritis, 2 with SSSS. (2 cases are omitted from evaluation because of Mycoplasma pneumonia and infectious mononucleosis). Daily dosages per kg bodyweight ranging from 18.3 to 60 mg were given in 3 divided doses per day for 4 to 6 days. Clinical responses were excellent in 12 (80%), good in 2 (13.3%), fair in 1 (6.7%) and poor in 0 (0%), with an overall efficacy rate of 93.3%. Good bacteriological responses were obtained in all of the 9 cases from which pathogens were identified. A side effect is observed in only 1 case with mild diarrhea. The above results suggest that L-627 is a useful new carbapenem derivative for the treatment of bacterial infections in children.
Insights
Biapenem (L-627), a novel carbapenem, demonstrated high efficacy in treating acute bacterial infections in children. This antibiotic showed a 93.3% overall clinical efficacy rate with minimal side effects.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Therapy
- Carbapenem Antibiotics
Background:
- Acute bacterial infections pose a significant health challenge in pediatric populations.
- Carbapenem antibiotics are crucial for treating severe bacterial infections.
- Evaluating novel carbapenem derivatives is essential for expanding treatment options.
Purpose of the Study:
- To assess the clinical efficacy and safety of biapenem (L-627) in children with acute bacterial infections.
- To determine the bacteriological response to biapenem treatment.
- To identify any adverse effects associated with biapenem administration in pediatric patients.
Main Methods:
- Intravenous administration of biapenem (L-627) to 17 children with various acute bacterial infections.
- Dosages ranged from 18.3 to 60 mg/kg/day, divided into three doses for 4-6 days.
- Clinical and bacteriological responses, along with side effects, were systematically evaluated.
Main Results:
- An overall clinical efficacy rate of 93.3% was observed, with 80% excellent and 13.3% good responses.
- Good bacteriological responses were achieved in all 9 cases where pathogens were identified.
- Only one case reported a mild side effect (diarrhea), indicating a favorable safety profile.
Conclusions:
- Biapenem (L-627) is a highly effective and well-tolerated carbapenem derivative for treating bacterial infections in children.
- The study supports the potential of biapenem as a valuable therapeutic option in pediatric infectious disease management.
- Further research may explore broader applications and long-term outcomes of biapenem in pediatric patients.